Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Affymax's Share Price Stumbles On Questionable Phase III Hematide Data

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase III data for Affymax/Takeda's anemia drug for chronic kidney failure signals potential regulatory hurdles in non-dialysis use.
Advertisement

Related Content

Affymax Plans For Peginesatide Launch
Affymax Plans For Peginesatide Launch
CMS Begins National Coverage Determination Process For ESAs In The Renal Setting
Access To ESRD Drugs Under Bundled Medicare Payments Concerns GAO
AMAG Pharmaceuticals Irons Out Ex-US Deal With Takeda For Feraheme
ESA REMS Allows Oncology Providers One Year To Enroll Before Possible Distribution Limits
ESA REMS Allows Oncology Providers One Year To Enroll Before Possible Distribution Limits

Topics

Advertisement
UsernamePublicRestriction

Register

PS070784

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel